Picture the hallway outside the New Orleans convention floor on Friday afternoon. Aaron Kelly, a pediatric obesity researcher from Minnesota, is standing there with a stack of paper in his hands. A man wearing a Constable’s badge walks up and shoves him, while Louisiana State Police hover a step behind. A plainclothes security guy walks straight at Steven Kahn, the editor-in-chief of Diabetes Care, and yanks a sheaf of pages out of Kahn’s fists. MedPage Today’s camera is rolling. Five American Diabetes Association registrants get walked out of the building by officers.

The pages were an editorial from Kahn’s own journal, co-written in April with three other senior diabetes researchers, and the title alone tells you the temperature: “Misguided Brushes of a Pen Continue to Dismantle and Destroy Biomedical Research in the United States: We Can No Longer Afford Complacency and Fear. We Must All Act Now!” The text is a sustained attack on the Trump administration’s NIH overhaul, the proposed roughly forty-percent cut to the agency’s $46 billion budget, the grant freezes, and a plan to consolidate the existing 27 institutes down to 8.

Two things can be true at once, and on this story they are. The shove was bad, full stop. The editorial getting shoved is also doing some laundering most of the press is missing.

Start with the cop part, because it’s the part that doesn’t need any nuance. A constable putting hands on a credentialed academic for passing out a peer-reviewed editorial from his own journal is not a serious response to dissent. It looks bad. It is bad. Officers walking five doctors out of a conference center for distributing pages from Diabetes Care is the kind of image that makes the people who did the shoving look like the villains of the story, which is exactly the framing most of the press has run with since Friday afternoon.

That part needs no reframe. The rest does.

Read the editorial and look at who signed it. Kahn edits Diabetes Care. Cheryl Anderson runs a public-health school. The third name on the list is John B. Buse, whose published disclosures report consulting and research ties to Novo Nordisk, Eli Lilly, and a long list of other diabetes drugmakers, and who is a named author on Novo Nordisk’s SOUL trial of oral semaglutide. Elizabeth Selvin is a Hopkins epidemiologist whose career is wired into NIH grant flow. The piece discloses ADA editor honoraria and NIH grant support and reports no other relevant conflicts, so the disclosure is not absent. It is also not complete. Nothing in the disclosure tells the reader that the journal these editors edit is owned by the American Diabetes Association, whose annual Scientific Sessions sit on a convention floor thick with corporate symposia from Novo Nordisk, Lilly, Sanofi, and AstraZeneca, the same companies whose GLP-1 and insulin franchises dominate the field’s drug pipeline.

You don’t have to assume bad faith to notice that an ADA-owned specialty journal publishing its editor’s political case against NIH reform, signed by senior trialists deep in the pharma-funded literature, is structurally not the same thing as scientific consensus. It is a guild defending the shape of the money. It might also be right about parts of the threat. Both can be true.

Now look at what the editorial is actually opposing. The MAHA-aligned agenda Bhattacharya’s NIH has been pushing, delivered as Friday’s keynote by his senior advisor Richard Woychik after Bhattacharya canceled to meet with Trump, says diabetes research needs to integrate environmental exposures, diet, and chronic chemical exposure work alongside the existing drug-trial model. Woychik told the room directly: “I could have written the MAHA agenda.” He talked about studying biological responses to vaccines without banning them, taking the conflicting fluoride-and-cognition data seriously, and treating both genetic and environmental factors in autism as live questions worth funding. He framed it as an exposome, root-cause approach. None of that is the kind of “dismantling” the editorial describes.

The chronic-disease arithmetic is what makes the framing strange. CDC currently puts 40.1 million Americans (about one in eight) with diagnosed diabetes, and 115.2 million adults (more than two in five) with prediabetes, with roughly eight in ten of those people unaware they have it. The pediatric obesity field whose own researcher got shoved on Friday is the same field whose dominant guideline body, the American Academy of Pediatrics, recommended in 2023 that GLP-1 pharmacotherapy be offered to children twelve and up with obesity and that bariatric-surgery referrals start at thirteen for severe obesity. Under the existing biomedical-research consensus the disease curves have gotten worse, not better, while the drug pipeline has gotten fuller and more expensive. A federal research priority that takes prevention, food environment, metabolic disruption, and lifestyle-intervention work seriously is what diabetes has been asking for. The editorial frames it as a threat.

There is one piece of the actual proposal worth watching from the other direction. The original White House FY26 request did not just consolidate NIH institutes. It would have eliminated the National Center for Complementary and Integrative Health outright, the small $170 million unit that has been the only federal home for nutrition, supplement, mind-body, and lifestyle-trial research. Congress rejected the deepest cuts in February and restored NCCIH funding at the prior year’s level. So the MAHA pitch about elevating integrative research and the actual Trump budget were, on paper, pulling in opposite directions: one talked exposome and root cause, the other zeroed out the integrative-research line. Where the next round of NIH dollars actually lands inside any consolidated structure is the part that decides whether any of this reaches a kid with prediabetes.

So here is what I make of Friday. The footage of the shove is going to get used to argue that any reorganization of the NIH grant system is state suppression of science, and it is not. The grant system is a closed loop in the structural sense that NIH funding is heavily concentrated in a small set of R1 institutions and disease guilds whose flagship journals run on industry money, and the editors who had their literature ripped out of their hands sit comfortably inside that loop. They are not wrong to defend the parts of biomedical research that serve the public. They are also not the credible defenders of the parts that have failed the public for decades. The story worth following from here is whether the consolidated NIH actually funds the prevention and exposome work the MAHA pitch keeps promising, or whether the guilds turn one bad cop encounter into another decade of business as usual for diabetes care that hands twelve-year-olds GLP-1 prescriptions and calls it progress.

Sources

  1. Diabetes Care – Misguided Brushes of a Pen Continue to Dismantle and Destroy Biomedical Research in the United States (2026)
  2. STAT News – Senior NIH official pushes MAHA priorities to skeptical ADA audience (2026)
  3. STAT News – NIH funding: national researcher survey finds cutbacks, disruptions (2026)
  4. Diabetes Care – Impact of Oral Semaglutide on Kidney Outcomes (SOUL trial); author disclosures include J.B. Buse (2026)